The 6 analysts offering 12-month price forecasts for Rubius Therapeutics Inc have a median target of 30.50, with a high estimate of 40.00 and a low estimate of 20.00. The median estimate represents a +64.16% increase from the last price of 18.58.
The current consensus among 6 polled investment analysts is to Buy stock in Rubius Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.55
Reporting Date Nov 17
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.